Serum Institute’s Covishield Vaccine Produces Antibodies Against B.1.617.1 Variant Of Coronavirus: ICMR Study

·1-min read

The Covishield Covid-19 vaccine, which is being manufactured in India by Serum Institute of India, is effective against the B.1.617.1 strain of the Coronavirus, a study has found.

The B.1.617.1 variant of the Covid-19 virus is considered to be responsible for surge of the cases in India.

A study by the Indian Council of Medical Research (ICMR) has concluded that "Covishield vaccine-induced antibodies are likely to be protective to limit the severity and mortality of the disease in vaccinated individuals”.

"The results demonstrated that sera of COVID-19 recovered subjects (n=18) who received two doses of Covishield have higher NAb response compared to the COVID-19 naive with a significant difference (p<0.0001) in NAb titer against B.1 and B.1.617.1," said the study published in pre-print server bioRxiv.

Till date, over 170 million doses of vaccine have been administered to Indian citizens with two approved vaccines- Covishield (Astrazeneca-Oxford) and Bharat Biotech's Covaxin.

Earlier, the ICMR in a study has said that the indigenous Covid-19 vaccine was effective against the various strains of the Covid-19 virus including B.1.617.1, B.1.1.7, B.1.1.28.2 and variants.